Real-World First-Line Serplulimab-Based Immunochemotherapy for Extensive-Stage Small Cell Lung Cancer: The Multicenter ASTRUM-005R Study

被引：0
|
作者：
Wu, L. [1 ]
Hu, C. [2 ]
Su, W. [3 ]
Yu, Y. [4 ]
Hong, W. [5 ]
Liu, Z. [6 ,8 ]
Su, H. [7 ]
Liu, Z. [6 ,8 ]
Wang, C. [9 ]
Pu, Q. [10 ]
Guo, H. [11 ]
Min, X. [12 ]
Chen, Y. [3 ]
Zhu, H. [13 ]
Luo, T. [14 ]
机构：
[1] Hunan Canc Hosp, Changsha, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Changsha, Hunan, Peoples R China
[3] Chinese Acad Med Sci, Canc Hosp, Shanxi Hosp, Taiyuan, Peoples R China
[4] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[5] Univ Chinese Acad Sci, Dept Chest Oncol, Canc Hosp, Beijing, Peoples R China
[6] Southern Med Univ, Affiliated Hosp 10, Dongguan Peoples Hosp, Dongguan, Peoples R China
[7] Air Force Med Univ, Xian, Peoples R China
[8] Jiangxi Canc Hosp, Nanchang, Jiangxi, Peoples R China
[9] Shandong First Med Univ, Shandong Prov Hosp, Jinan, Shandong, Peoples R China
[10] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China
[11] Xi An Jiao Tong Univ, Affiliated Hosp 2, Xian, Peoples R China
[12] AN HUI CHEST Hosp, Hefei, Anhui, Peoples R China
[13] Shandong First Med Univ, Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Jinan, Shandong, Peoples R China
[14] Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Extensive-stage small cell lung cancer; PD-1; inhibitor; Serplulimab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.13A.07
引用
收藏
页码：S209 / S209
页数：1
相关论文
共 50 条
  • [31] Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).
    Nadler, Eric S.
    Vasudevan, Anupama
    Davies, Kalatu
    Wang, Yunfei
    Johnson, Ann
    Ogale, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] A real-world multicentre evaluation of atezolizumab plus platinum-etoposide chemotherapy as first-line treatment in patients with extensive-stage small cell lung cancer in Italy
    Musicco, Felice
    Fulgenzio, Chiara
    La Malfa, Antonia
    Jannitti, Nicoletta
    Vitiello, Antonietta
    Carpano, Silvia
    Fusco, Francesca
    Cappuzzo, Federico
    Terrenato, Irene
    Sperduti, Isabella
    Polidori, Piera
    Tarantino, Domenico
    Di Cerbo, Lidia
    Pani, Marcello
    Isgro, Valentina
    Lasala, Ruggero
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024,
  • [33] Real-World Outcomes of Platinum-immunotherapy as First-Line (1L) Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Ganti, A. K.
    Prince, T.
    Back, S.
    Chansakul, A.
    Boccuti, A.
    Rengarajan, B.
    Chakrabarti, D.
    Li, W.
    Fan, L.
    Cao, Y.
    D'Agostino, R., Jr.
    Fan, X.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S664 - S665
  • [34] Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer
    Shaw, Jaime
    Pundole, Xerxes
    Balasubramanian, Akhila
    Anderson, Erik S.
    Pastel, Malaika
    Bebb, D. Gwyn
    Jiang, Tony
    Martinez, Pablo
    Ramalingam, Suresh S.
    Borghaei, Hossein
    ONCOLOGIST, 2024, 29 (12): : 1079 - 1089
  • [35] Real-world evaluation of first-line treatment of extensive-stage small-cell lung cancer with atezolizumab plus platinum/etoposide: a focus on patients with brain metastasis
    Chen, Hanxiao
    Ma, Xiangjuan
    Liu, Jie
    Yang, Yu
    He, Yanhui
    Fang, Yong
    Wang, Liping
    Fang, Jian
    Zhao, Jun
    Zhuo, Minglei
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1664 - 1673
  • [36] Association Between Sarcopenia, Clinical Outcomes, and Survival in Patients with Extensive-Stage Small Cell Lung Cancer Treated with First-Line Immunochemotherapy: A Prospective Cohort Study
    Tian, Le
    Huang, Jia-Xin
    Wan, Rui
    Zhang, Jie
    Zhang, Xi
    Li, Ning
    Li, Na
    Liu, Xin-Qi
    Song, Chen-Xin
    Wang, Xin-Yi
    Yu, Lei
    Wang, Shao-Ming
    Wang, Zhi-Jie
    Cong, Ming-Hua
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2025, 77 (01): : 62 - 69
  • [37] First-line apatinib plus chemotherapy in extensive-stage small-cell lung cancer.
    Shi, Jian
    Liu, Jiayin
    Duan, Xiaoyang
    Huang, Guanglei
    Wang, Lixing
    Zhao, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
    Wang, Yingcheng
    Rui, Mingjun
    Yang, Lan
    Wang, Xintian
    Shang, Ye
    Ma, Aixia
    Li, Hongchao
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
  • [39] Serplulimab vs. placebo combined with chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: Extended follow-up results and patient-reported outcomes from the international phase 3 ASTRUM-005 study.
    Cheng, Ying
    Han, Liang
    Wu, Lin
    Chen, Jun
    Sun, Hongmei
    Wen, Guilan
    Ji, Yinghua
    Zimina, Anastasia V.
    Shi, Jianhua
    Pan, Zhijie
    Shi, Jinsheng
    Wang, Xicheng
    Bai, Yuansong
    Melkadze, Tamar
    Pan, Yueyin
    Min, Xuhong
    Viguro, Maksym
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A Spanish phase IIIb single arm, real-world study
    Paz-Ares, L.
    Arriola, E.
    Campelo, M. R. Garcia
    Tain, M. P. Diz
    Blanco, M. C. Marti
    Vega, A. L. Moreno
    Leon-Mateos, L.
    Calderon, V. Gutierrez
    Hernandez, A. Sanchez
    Rodriguez, J. M. Oramas
    Majem, M.
    De la Rosa, C. Aguado
    Cabellos, R. Alvarez
    Ciriquian, J. L. Marti
    Amezcua, V.
    Perez, J. L. Firvida
    Mellen, A. Callejo
    Baez, L.
    Isla, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S1171 - S1172
12345